ArticleFrontiers in neurology2025
Predicting cognitive impairment in Parkinson's disease: a machine learning approach based on clinical and neuropsychological data.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cognitive impairment is a common and disabling non-motor symptom of Parkinson's disease, markedly diminishing quality of life and elevating caregiver burden. Although considerable research has been conducted, the early prediction of cognitive impairment remains challenging owing to heterogeneous clinical presentations, variations in treatment adherence, and the inherent limitations in sensitivity of conventional biomarkers and cognitive assessment tools. Methods and materials: A retrospective cohort study involving 514 Parkinson's disease patients who had complete baseline data and a minimum of 6 months of follow-up. Participants were randomly allocated into a training cohort ( Results: During follow-up, patients who developed cognitive impairment were significantly older and had longer disease duration, lower levels of albumin, hematocrit, and blood lipids, as well as a higher prevalence of hypertension. Feature selection identified: Age, Platelet count, Time from diagnosis to baseline visit, Apolipoprotein B, and Hematocrit as the predictors. The Random Forest model demonstrated the best overall performance, with the area under the receiver operating characteristic curve = 0.846, accuracy = 0.75, and an F1-score = 0.775, followed by CatBoost and Logistic Regression. Calibration and decision curve analyses confirmed stable probability estimation and superior clinical utility of Random Forest compared with "treat all" or "treat none" strategies. Further use the Montreal Cognitive Assessment score to verify the stability of the model. Conclusion: Machine learning models integrating multimodal clinical and neuropsychological data demonstrate high accuracy in predicting cognitive impairment in Parkinson's disease, with Random Forest emerging as the most reliable approach. This framework provides a practical tool for early risk stratification, potentially enabling timely interventions and individualized management to reduce the burden of cognitive decline in Parkinson's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.